초록 ▼

Topical pharmaceutical compositions containing a corticosteroid component and a penetration-enhancing vehicle are disclosed. The vehicle comprises a binary combination of a C 3 -C 4 diol and a "cell-envelope disordering compound". The vehicle provides marked transepidermal and percutaneous delivery

Topical pharmaceutical compositions containing a corticosteroid component and a penetration-enhancing vehicle are disclosed. The vehicle comprises a binary combination of a C 3 -C 4 diol and a "cell-envelope disordering compound". The vehicle provides marked transepidermal and percutaneous delivery of corticosteroids. A method of treating certain rheumatic and inflammatory conditions, systemically or locally, is also disclosed.

대표청구항 ▼

1. A penetration-enhancing pharmaceutical composition for topical application, comprising: (a) a safe and effective amount of a pharmaceutically-active corticosteroid; (b) 0% to about 80% by weight of a solvent selected from the group consisting of water, ethanol or 2-propanol; and (c) about 10

1. A penetration-enhancing pharmaceutical composition for topical application, comprising: (a) a safe and effective amount of a pharmaceutically-active corticosteroid; (b) 0% to about 80% by weight of a solvent selected from the group consisting of water, ethanol or 2-propanol; and (c) about 10% to about 99.9% by weight of a penetration-enhancing carrier consisting essentially of: (i) a diol selected from the group consisting of 1,2-propanediol, 1-2,-butanediol, 1,3-butanediol, 2,3-butanediol, or mixtures thereof, and (ii) a cell-envelope disordering compound selected from the group consisting of methyl laurate, oleic acid, myristyl alcohol, or mixtures thereof; wherein said diol and said cell-envelope disordering compound are present in a ratio of diol:cell-envelope disordering compound of from about 1:1 to about 500:1 by weight; and wherein said penetration-enhancing composition is substantially free from any single member of the C 16 -C 20 straight chain, saturated normal fatty alcohols, and C 4 -C 20 straight chain, saturated mono- or dicarboxylic acids. 2. A composition according to claim 1 wherein the cell-envelope disordering compound is methyl laurate. 3. A composition according to claim 1 wherein the cell-envelope disordering compound is oleic acid. 4. A composition according to claim 1 wherein the cell-envelope disordering compound is myristyl alcohol. 5. A composition according to claim 1 wherein the level of any specific member of the C 16 -C 20 straight chain, saturated normal fatty alcohols, and C 4 -C 20 straight chain, saturated mono- or dicarboxylic acids is less than about 3.5% by weight. 6. A composition according to claim 5 wherein the level of any specific member of the C 16 -C 20 straight chain, saturated normal fatty alcohols, and C 4 -C 20 straight chain, saturated mono- or dicarboxylic acids is less than about 1% by weight. 7. A composition according to claim 1, which is substantially free from octanoic acid, decanoic acid, cetyl alcohol and stearyl alcohol. 8. A penetration-enhancing pharmaceutical composition for topical application, comprising: (a) about 0.05% to about 5%, by weight of a corticosteroid selected from the group consisting of triamcinolone acetonide, hydrocortisone acetate, betamethasone valerate, fluocinolone acetonide, flupamesone, or mixtures thereof; (b) 0% to about 80% by weight of a solvent selected from the group consisting of water, ethanol or 2-propanol; and (c) about 10% to about 99.9% by weight of a penetration-enhancing carrier consisting essentially of: (i) a diol selected from the group consisting of 1,2-propanediol, 1,2-butanediol, or mixtures thereof, (ii) a cell-envelope disordering compound selected from the group consisting of methyl laurate, oleic acid, myristyl alcohol, or mixtures thereof; wherein said diol and said cell-envelope disordering compound are present in a ratio of diol:cell-envelope disordering compound of from about 10:1 to about 100:1 by weight; and wherein said penetration-enhancing composition is substantially free from any specific member of the C 16 -C 20 straight chain, saturated normal fatty alcohols, and C 4 -C 20 straight chain, saturated mono- or dicarboxylic acids. 9. A composition according to claim 8 wherein the diol compound is 1,2-propanediol. 10. A composition according to claim 8 wherein the diol compound is 1,2-butanediol. 11. A composition according to claim 8 wherein the cell-envelope disordering compound is oleic acid. 12. A composition according to claim 8 wherein the cell-envelope disordering compound is myristyl alcohol. 13. A composition according to claim 8 wherein the level of any specific member of the C 16 -C 20 straight chain, saturated normal fatty alcohols, and C 4 -C 20 straight chain, saturated mono- or dicarboxylic acids is less than about 3.5% by weight. 14. A composition according to claim 13 wherein the level of any specific member of the C 16 -C 20 straight chain, saturated normal fatty alcohols, and C 4 -C 20 straight chain, saturated mono- or dicarboxylic acids is less than about 1% by weight. 15. A composition according to claim 8 which is substantially free from octanoic acid, decanoic acid, cetyl alcohol and stearyl alcohol. 16. A method of treating nonendocrine immunologic, rheumatic, hypersensitivity or inflammatory conditions in humans or lower animals comprising topically applying to a human or animal in need of such treatment a safe and effective amount of a composition according to claim 1. 17. A method according to claim 16 wherein the rheumatic or inflammatory condition is arthritis. 18. A method according to claim 16 wherein the rheumatic or inflammatory condition is rheumatic fever. 19. A method according to claim 16 wherein the hypersensitivity reaction is bronchial asthma. 20. A method according to claim 16 wherein the hypersensitivity reaction is anaphylaxsis. 21. A method according to claim 16 wherein the inflammatory condition is dermatitis. 22. A method according to claim 16 wherein the composition is applied at an application situs for systemic treatment. 23. A method according to claim 22 wherein the composition is applied from a sustained release device. 24. A method according to claim 21 wherein the composition is applied topically to the afflicted situs. 25. A method of treating nonendocrine immunologic, rheumatic, hypersensitivity or inflammatory conditions in humans or lower animals comprising topically applying a to human or animal in need of such treatment a safe and effective amount of a composition according to claim 8. 26. A method according to claim 25 wherein the rheumatic or inflammatory condition is arthritis. 27. A method according to claim 25 wherein the rheumatic or inflammatory condition is rheumatic fever. 28. A method according to claim 25 wherein the hypersensitivity reaction is bronchial asthma. 29. A method according to claim 25 wherein the hypersensitivity reaction is anaphylaxsis. 30. A method according to claim 25 wherein the inflammatory condition is dermatitis. 31. A method according to claim 25 wherein the composition is applied at an application situs for systemic treatment. 32. A method according to claim 31 wherein the composition is applied from a sustained release device. 33. A method according to claim 30 wherein the composition is applied topically to the afflicted situs. 34. A penetration-enhancing pharmaceutical composition for topical application, comprising: (a) a safe and effective amount of a pharmaceutically-active corticosteroid; (b) 0% to about 80% by weight of a solvent selected from the group consisting of water, ethanol or 2-propanol; and (c) about 10% to about 99.9% by weight of a penetration-enhancing carrier consisting essentially of: (i) 1,2-butanediol, and (ii) a cell-envelope disordering compound selected from the group consisting of methyl laurate, oleic acid, oleyl alcohol, monoolein, myristyl alcohol, or mixtures thereof; wherein said 1,2-butanediol and said cell-envelope disordering compound are present in a ratio of diol:cell-envelope disordering compound of from about 1:1 to about 500:1 by weight; and wherein said penetration-enhancing composition is substantially free from any single member of the C 16 -C 20 straight chain, saturated normal fatty alcohols, and C 4 -C 20 straight chain, saturated mono- or dicarboxylic acids.